Celldex Therapeutics, Inc. $CLDX Shares Sold by Commodore Capital LP

Commodore Capital LP cut its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 12.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,028,335 shares of the biopharmaceutical company’s stock after selling 421,665 shares during the period. Celldex Therapeutics makes up 3.8% of Commodore Capital LP’s holdings, making the stock its 10th biggest holding. Commodore Capital LP’s holdings in Celldex Therapeutics were worth $78,343,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Vestal Point Capital LP increased its holdings in shares of Celldex Therapeutics by 781.0% during the 2nd quarter. Vestal Point Capital LP now owns 1,750,000 shares of the biopharmaceutical company’s stock worth $35,612,000 after buying an additional 1,551,354 shares during the last quarter. Braidwell LP acquired a new stake in Celldex Therapeutics during the third quarter worth $15,307,000. Wellington Management Group LLP raised its position in Celldex Therapeutics by 10.8% in the third quarter. Wellington Management Group LLP now owns 5,800,003 shares of the biopharmaceutical company’s stock valued at $150,046,000 after purchasing an additional 567,677 shares during the period. Segall Bryant & Hamill LLC acquired a new position in shares of Celldex Therapeutics in the 2nd quarter valued at $7,894,000. Finally, Millennium Management LLC lifted its stake in shares of Celldex Therapeutics by 327.3% in the 1st quarter. Millennium Management LLC now owns 399,932 shares of the biopharmaceutical company’s stock valued at $7,259,000 after purchasing an additional 306,330 shares during the last quarter.

Celldex Therapeutics Stock Performance

NASDAQ CLDX opened at $29.51 on Friday. The firm has a market cap of $1.96 billion, a price-to-earnings ratio of -7.59 and a beta of 1.17. The firm has a 50 day simple moving average of $26.34 and a 200-day simple moving average of $25.98. Celldex Therapeutics, Inc. has a one year low of $14.40 and a one year high of $31.99.

Celldex Therapeutics (NASDAQ:CLDX) last released its earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($1.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.22). The business had revenue of $0.12 million for the quarter, compared to analyst estimates of $1.53 million. Celldex Therapeutics had a negative return on equity of 41.67% and a negative net margin of 3,446.88%. Equities analysts predict that Celldex Therapeutics, Inc. will post -2.48 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently issued reports on CLDX. Weiss Ratings restated a “sell (d-)” rating on shares of Celldex Therapeutics in a report on Wednesday, January 21st. Barclays boosted their price target on shares of Celldex Therapeutics from $21.00 to $24.00 and gave the company an “underweight” rating in a research note on Wednesday, December 17th. The Goldman Sachs Group lifted their target price on shares of Celldex Therapeutics from $30.00 to $34.00 and gave the company a “neutral” rating in a report on Monday, March 2nd. Finally, Stifel Nicolaus restated a “buy” rating and set a $68.00 price target (up from $58.00) on shares of Celldex Therapeutics in a research note on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $44.50.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.